Skip to content
Est. 1998 proudly celebrating our 27th year of championing American business
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Grifols SA

$7.33 -4.06% NASDAQ: GRFS · 15-min delayed
  • NEW YORK, New York
  • Public · NASDAQ: GRFS
  • 25,247 employees
$5.2BMarket cap
25,247Employees
GRFSNASDAQ
2011IPO

About Grifols SA

Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Market cap
$5.2B
NASDAQ: GRFS
$7.33 -4.06%

15-minute delayed · data by Polygon.io

Past year

$7.10 $10.85

52-week range

Market cap
$5.2B
Shares outstanding
709.4M
Open
Day range
Prev close
Volume
IPO date
Jun 2, 2011

Market data by Polygon.io · prices are 15-minute delayed

Auto-generated

At a glance

  • Trading 32% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Grifols SA.

Write a review
Newsroom

News about Grifols SA

News & sentiment via Polygon.io

Explore

Similar companies

Browse all →